Budesonide Inhalant
Product Images NDC 0487-9701

16 FDA label images from Nephron Pharmaceuticals Corporation · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Budesonide (NDC 0487-9701). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nephron Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Budesonide 01)

Chemical Structure (Budesonide 01)
Chemical structure of budesonide showing its steroid backbone with oxygen-containing functional groups and side chains, as part of the inhalant medication by Nephron Pharmaceuticals Corporation.*
FDA Label Image

Figure 1: A 12-week Trial In Pediatric Patients Not On Inhaled Corticosteroid Therapy Prior To Study Entry. Nighttime Asthma Change From Baseline (Bud Fig 1)

Figure 1: A 12-week Trial In Pediatric Patients Not On Inhaled Corticosteroid Therapy Prior To Study Entry. Nighttime Asthma Change From Baseline (Bud Fig 1)
A line graph showing mean change from baseline in mean asthma symptom scores over different weeks for placebo and three doses of Budesonide inhalant (0.25 mg, 0.5 mg, 1.0 mg daily). The x-axis represents time in weeks and the y-axis shows change from baseline in symptom scores. P-values for each dose are noted.*
FDA Label Image

Figure 1 (Budesonide 02)

Figure 1 (Budesonide 02)
A line graph showing mean change from baseline in nighttime asthma symptoms over a 12-week period. It compares three groups: placebo, 0.25 mg twice daily, and 0.5 mg twice daily dosages of Budesonide inhalant. The y-axis measures mean change from baseline, ranging from -0.6 to 0.1, and the x-axis represents time intervals from baseline through week 0 to 12.*
FDA Label Image

Figure 3: A 12-week Trial In Pediatric Patients Either Maintained On Bronchodilators Alone Or Inhaled Corticosteroid Therapy Prior To Study Entry. Nighttime Asthma Change From Baseline. (Bud Fig 3)

Figure 3: A 12-week Trial In Pediatric Patients Either Maintained On Bronchodilators Alone Or Inhaled Corticosteroid Therapy Prior To Study Entry. Nighttime Asthma Change From Baseline. (Bud Fig 3)
A line graph showing the mean change from baseline in nighttime asthma symptoms over a 12-week period for different dosing regimens of Budesonide inhalant compared to placebo. The x-axis represents time intervals from baseline through 12 weeks, while the y-axis shows the mean change in symptoms. Each line corresponds to a dosing group: placebo, 0.25 mg once daily, 0.25 mg twice daily, 0.5 mg twice daily, and 1.0 mg once daily.*
FDA Label Image

Figure 1 And 1a (Figure 1 And 1.0a)

Figure 1 And 1a (Figure 1 And 1.0a)
An instructional diagram showing how to handle and open single-dose ampules of Budesonide inhalant solution. Figure 1 depicts hands holding multiple sealed ampules in a strip. Figure 1a shows a hand opening the top of an individual ampule by snapping off the neck.*
FDA Label Image

Figure 2 (Budesonide Ifu Figure 2.0)

Figure 2 (Budesonide Ifu Figure 2.0)
An instructional illustration labeled 'Figure 2' showing a close-up of a hand holding an inhalant device. The thumb is positioned to rotate or twist the cap or a component of the device, indicated by a curved arrow, suggesting the method to open or activate the inhalant for use.*
FDA Label Image

Figure 3 (Budesonide Ifu Figure 3.0)

Figure 3 (Budesonide Ifu Figure 3.0)
An instructional illustration labeled "Figure 3" showing a pair of hands holding and manipulating an inhalant device, demonstrating its proper use or assembly related to Budesonide inhalant.*
FDA Label Image

Figure 4 (Budesonide Ifu Figure 4.0)

Figure 4 (Budesonide Ifu Figure 4.0)
An instructional illustration showing a person holding a cup in one hand while using the other hand to dispense liquid from a dropper or similar applicator into the cup. The image is labeled as Figure 4, suggesting it is part of a series of instructions, likely related to the proper use or administration of Budesonide inhalant.*
FDA Label Image

Single Foil (547 Single)

Single Foil (547 Single)
Budesonide Inhalation Suspension 0.25 mg/2 mL single-dose plastic ampule label by Nephron Pharmaceuticals Corporation. The label includes directions for inhalation use only, storage instructions, and a barcode. It indicates the ampule contains 2 mL of sterile suspension with 0.25 mg micronized budesonide and inactives. The label states Rx only and provides customer service contact details.*
FDA Label Image

Single Carton 1115 (Bud Single Cart 1115)

Single Carton 1115 (Bud Single Cart 1115)
Packaging label for Budesonide Inhalation Suspension 0.25 mg/2 mL by Nephron Pharmaceuticals Corporation. The label indicates it contains 30 plastic single-dose ampules, each in a foil pouch, for inhalation use only. Instructions for use with illustrations are included on the carton. The product is marked Rx Only and is made in the USA.*
FDA Label Image

Card Foil (549 Card)

Card Foil (549 Card)
Label for Budesonide Inhalation Suspension 0.25 mg/2 mL single-dose plastic ampules. The label lists usage instructions and storage conditions, emphasizing use with a jet nebulizer only. Manufactured by Nephron Pharmaceuticals Corporation, this product is for respiratory inhalation and contains five 2 mL ampules per package.*
FDA Label Image

1118 Carton (1118 Carton Card New)

1118 Carton (1118 Carton Card New)
Packaging label of Budesonide 0.25 mg/2 mL inhalation suspension by Nephron Pharmaceuticals Corporation. The box contains 30 (6 pouches x 5) 2 mL plastic single-dose ampules for inhalation only. The label includes storage instructions and manufacturer details, noting the product is made in the USA.*
FDA Label Image

Single Foil (545 Singles)

Single Foil (545 Singles)
Label for Budesonide Inhalation Suspension 0.5 mg/2 mL, a respiratory inhalant by Nephron Pharmaceuticals Corporation. The label states it is a single-dose plastic ampule containing 2 mL. Instructions include storage conditions, use only in jet nebulizer, and contents use immediately after opening. Barcode and manufacturer contact information are also visible.*
FDA Label Image

Carton Single 1116 (Carton 1116)

Carton Single 1116 (Carton 1116)
Packaging label for Budesonide Inhalation Suspension 0.5 mg/2 mL by Nephron Pharmaceuticals Corporation. The label indicates 30 plastic single-dose ampules per carton, each in a foil pouch. The packaging includes instructions for use and storage directions. The product is marked as Rx only and for inhalation use only.*
FDA Label Image

Foil Card 550 (550 Card)

Foil Card 550 (550 Card)
Label for Budesonide Inhalation Suspension 0.5 mg/2 mL by Nephron Pharmaceuticals Corporation. The packaging contains 5 single-dose 2 mL plastic ampules for inhalation use only. Instructions on use, storage, and handling are included, emphasizing use in a jet nebulizer, protecting from light, and proper storage temperature. The label includes a barcode and contact information for customer service.*
FDA Label Image

1117 Carton (1117 Carton Card New)

1117 Carton (1117 Carton Card New)
Packaging label for Budesonide inhalation suspension 0.5 mg/2 mL by Nephron Pharmaceuticals Corporation. The carton contains 30 single-dose 2 mL plastic ampules for inhalation only, organized in 6 pouches of 5 ampules each. The label includes usage instructions and storage information with the NDC 0487-9701-30.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.